Email this Page To a Friend |
![]() |
U.S. Food and
Drug Administration
FDA Consumer magazine
November-December 2001
Table
of Contents
[Photos of Health and Human Services Secretary Tommy Thompson at Ground Zero]
Health and Human Services Secretary Tommy G. Thompson says that his agency's quick reaction to the terrorist attacks on New York City and Washington, D.C., demonstrated a high degree of preparedness. Nevertheless, Thompson says "there is more we can do--and must do--to strengthen our response."
In the days and weeks following the Sept. 11 terrorist attacks against the World Trade Center and the Pentagon, Thompson saw the destruction firsthand. He directed relief efforts ranging from disbursing emergency funds to those who suffered losses in the attacks to urging food industry trade groups to review their security plans.
Thompson also has worked to address concerns about biological and chemical assaults that have surged to the forefront since the attacks. Priorities listed by Thompson during his testimony on bioterrorism before a Senate subcommittee in October include:
Efforts at the FDA since Sept. 11 have focused on the protection of regulated products (foods and animal feed, radiologic devices, the blood supply, drugs, and vaccines) from contamination and tampering. In addition, the FDA staff has worked to ensure the availability of medical products (drugs, vaccines, and devices) necessary to public health preparedness for use against anthrax and other biological, chemical, or nuclear agents.
The FDA is working to build upon current surveillance capacities and to provide support for the detection and management of possible cases of product contamination. The agency also is developing strategies to seize illicit or contaminated products, to provide regulatory guidance to government agencies responsible for medical products in a public health emergency, and to communicate with manufacturers to ensure the availability of products needed to treat a biological agent.
See
also
"Anthrax Prevention and Treatment"
Table
of Contents | How
to Subscribe |
Back Issues | Editorial
Questions
FDA/Office
of Public Affairs
Web page created by clb
2001-OCT-29.